Search results
Results from the WOW.Com Content Network
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
California State University, Fresno – The Daily Collegian; California State University, Fullerton – The Daily Titan; California State University, Long Beach – 22 West Magazine, Daily Forty-Niner and DIG magazine; California State University, Los Angeles – University Times; California State University, Monterey Bay – The Lutrinae
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013. [5] In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. [6] In June 2015, the company acquired Cord Blood Registry for $700 million. [7] In 2014, AMAG acquired Lumara Health, formerly KV ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us